A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Status:
Terminated
Trial end date:
2018-07-10
Target enrollment:
Participant gender:
Summary
The study will examine the safety profile of SGN-CD19B administered as a single agent. The
main purpose of the study is to estimate the highest dose that does not cause unacceptable
side effects of SGN-CD19B in patients with relapsed or refractory aggressive B-cell
non-Hodgkin lymphoma (NHL) subtypes of diffuse large B-cell lymphoma (DLBCL) and Grade 3
follicular lymphoma (FL3). Additionally, the pharmacokinetic profile and antitumor activity
of SGN-CD19B will be assessed.